---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011500"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:09:07.902092+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Cyclerion enters exclusive talks to sell zagociguat/CY3018; CEO to invest $5M

## Summary
- Non-binding proposal from entity including CEO Peter Hecht to buy zagociguat and CY3018 assets.
- Independent Board concluded proposal merits pursuit; exclusive negotiation period underway.
- Binding agreement for CEO to invest $5M in cash for stock or convertible preferred stock.
- CEO equity investment closes 6 business days after definitive asset sale documents signed.
- Proceeds intended to support ongoing operations; deal subject to board and shareholder approvals.

## SEC filing metadata
- accession: 0000950170-23-011500
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017023011500/0000950170-23-011500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017023011500/cycn-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011500
- JSON: https://secwatch.observer/filing/0000950170-23-011500.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.